CAMP4 Therapeutics (Nasdaq: CAMP) reported that on July 15, 2026, its Board Compensation Committee granted a non-qualified stock option to purchase 8,000 shares of common stock to a new employee as an inducement grant under Nasdaq Listing Rule 5635(c)(4).
The option has a 10-year term and an exercise price of $4.21 per share, equal to the closing price on the grant date. Vesting occurs over four years: 25% after one year of employment, then the remaining shares vest in 36 equal monthly installments, subject to continued service. The grant is made under the company’s 2026 Inducement Plan and related stock option agreement.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CAMP
-10.51%
7 alerts
-10.51%Session close to close
-6.4%Trough in 3 hr 11 min
$218.61MMarket Cap
0.4xRel. Volume
In the Jul 20 session, CAMP declined 10.51%, reflecting a significant negative market reaction.
Argus tracked a trough of -6.4% from its starting point during tracking.
Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
The stock dropped -10.5% in the session following this news. -3.83% was the 24-hour reaction to CAMP...
Analysis
The stock dropped -10.5% in the session following this news. -3.83% was the 24-hour reaction to CAMP4’s April 28 preprint announcement. A strong negative response would add to dilution risk associated with the active S-3 shelf; short positioning was low, limiting that specific risk context.
Key Figures
Grant Date:July 15, 2026Option Shares:8,000 sharesOption Term:10 years+5 more
8 metrics
Grant DateJuly 15, 2026Inducement grant
Option Shares8,000 sharesNewly hired employee inducement grant
Option Term10 yearsNon-qualified stock option
Exercise Price$4.21 per shareEqual to closing price on the Grant Date
Vesting Period4 yearsSubject to continued employee service
Initial Vesting25%Vests on the one-year employment anniversary
Initial Vesting Date1-year anniversaryEmployee's first day of employment
Monthly Vesting36 equal monthly installmentsRemaining option shares after initial vesting
The preprint described regulatory RNA mapping and CMP-002 development for SYNGAP1.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Inducement-grant and other positive company updates produced mixed historical reactions, with three positive and two negative 24-hour moves.
Key Terms
non-qualified stock option, nasdaq listing rule 5635(c)(4), inducement grant
3 terms
non-qualified stock optionfinancial
"granted a non-qualified stock option to purchase 8,000 shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement grantfinancial
"the “Inducement Grant”"
An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.
CAMBRIDGE, Mass., July 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on July 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase 8,000 shares of the Company’s common stock to a newly hired employee of the Company as an inducement material to such employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
The Inducement Grant has a ten-year term and an exercise price per share of $4.21, which is equal to the closing price of CAMP4’s common stock as of the Grant Date.The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. The Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable non-qualified stock option agreement.
About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
What inducement stock option did CAMP4 Therapeutics (CAMP) grant on July 15, 2026?
CAMP4 Therapeutics granted a non-qualified stock option for 8,000 shares of common stock to a new employee. According to CAMP4 Therapeutics, this inducement grant was approved by the Board Compensation Committee under Nasdaq Listing Rule 5635(c)(4) on July 15, 2026.
What is the exercise price of the July 2026 CAMP4 Therapeutics (CAMP) inducement option?
The inducement option has an exercise price of $4.21 per share. According to CAMP4 Therapeutics, this price equals the closing market price of CAMP4 common stock on the July 15, 2026 grant date, in line with the terms of its 2026 Inducement Plan.
How does the CAMP4 Therapeutics (CAMP) inducement grant vest for the new employee?
The inducement option vests over four years. According to CAMP4 Therapeutics, 25% of the shares vest on the one-year anniversary of the employee’s first day, with the remaining shares vesting in 36 equal monthly installments, subject to continued service.
Under which plan was the July 2026 CAMP4 Therapeutics (CAMP) inducement option granted?
The option was granted under CAMP4 Therapeutics’ 2026 Inducement Plan. According to CAMP4 Therapeutics, the non-qualified stock option is also governed by an applicable stock option agreement that sets detailed terms and conditions for the inducement grant.
Why did CAMP4 Therapeutics (CAMP) use Nasdaq Listing Rule 5635(c)(4) for this stock option grant?
CAMP4 used Nasdaq Listing Rule 5635(c)(4) to grant a stock option as an employment inducement. According to CAMP4 Therapeutics, the 8,000-share option was considered material to the new employee’s decision to join the company, aligning with that rule’s requirements.
What is the term length of the CAMP4 Therapeutics (CAMP) inducement stock option granted in July 2026?
The inducement stock option has a 10-year term from the grant date. According to CAMP4 Therapeutics, the option may be exercised during this period, subject to vesting conditions and the employee’s continued service under the 2026 Inducement Plan.
